相似文献
1
Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility.
J Clin Microbiol. 1999 Sep;37(9):3068-71. doi: 10.1128/JCM.37.9.3068-3071.1999.
2
Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative.
Antimicrob Agents Chemother. 2001 Jan;45(1):349-52. doi: 10.1128/AAC.45.1.349-352.2001.
3
[The change in sensitivity of methicillin-resistant Staphylococcus aureus to vancomycin].
Zhonghua Nei Ke Za Zhi. 2002 Jan;41(1):31-3.
4
Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at three periods during 1991-1997.
Eur J Clin Microbiol Infect Dis. 2001 Jun;20(6):425-7. doi: 10.1007/pl00011284.
5
Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.
Chemotherapy. 1998 Sep-Oct;44(5):318-23. doi: 10.1159/000007129.
6
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.
J Clin Microbiol. 2006 Nov;44(11):3883-6. doi: 10.1128/JCM.01388-06. Epub 2006 Sep 6.
7
Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
J Infect Dis. 2002 Sep 1;186(5):661-7. doi: 10.1086/342708. Epub 2002 Aug 1.
8
An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital.
Clin Infect Dis. 2000 Nov;31(5):1306-8. doi: 10.1086/317464.
9
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
J Antimicrob Chemother. 2007 Oct;60(4):788-94. doi: 10.1093/jac/dkm258. Epub 2007 Jul 10.
10
Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.
Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.
引用本文的文献
1
Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India.
J Pharmacol Pharmacother. 2011 Jul;2(3):158-64. doi: 10.4103/0976-500X.83279.
2
In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Sep;55(9):3977-84. doi: 10.1128/AAC.00402-11. Epub 2011 Jul 5.
3
Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.
Antimicrob Agents Chemother. 2006 Jul;50(7):2577-82. doi: 10.1128/AAC.00260-06.
4
Laboratory detection and investigation of reduced susceptibility to vancomycin in oxacillin-resistant Staphylococcus aureus.
Eur J Clin Microbiol Infect Dis. 2003 Mar;22(3):199-201. doi: 10.1007/s10096-003-0895-5. Epub 2003 Mar 5.
5
Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit.
J Clin Microbiol. 2002 Jul;40(7):2520-5. doi: 10.1128/JCM.40.7.2520-2525.2002.
6
Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.
J Clin Microbiol. 2001 Jul;39(7):2439-44. doi: 10.1128/JCM.39.7.2439-2444.2001.
7
Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.
Antimicrob Agents Chemother. 2001 Apr;45(4):1292-4. doi: 10.1128/AAC.45.4.1292-1294.2001.
本文引用的文献
1
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.
Lancet. 1998 Apr 18;351(9110):1212. doi: 10.1016/s0140-6736(05)79166-2.
2
Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.
J Clin Microbiol. 1998 Apr;36(4):1020-7. doi: 10.1128/JCM.36.4.1020-1027.1998.
3
Vancomycin-resistant Staphylococcus aureus.
Lancet. 1998 Feb 21;351(9102):602. doi: 10.1016/S0140-6736(05)78597-4.
4
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
Lancet. 1997 Dec 6;350(9092):1670-3. doi: 10.1016/S0140-6736(97)07324-8.
5
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.
Clin Microbiol Rev. 1997 Oct;10(4):781-91. doi: 10.1128/CMR.10.4.781.
6
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
MMWR Morb Mortal Wkly Rep. 1997 Aug 22;46(33):765-6.
7
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
J Antimicrob Chemother. 1997 Jul;40(1):135-6. doi: 10.1093/jac/40.1.135.
8
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.
J Bacteriol. 1997 Apr;179(8):2557-66. doi: 10.1128/jb.179.8.2557-2566.1997.
9
Genetic control of population structure in heterogeneous strains of methicillin resistant Staphylococcus aureus.
Eur J Clin Microbiol Infect Dis. 1993;12 Suppl 1:S13-8. doi: 10.1007/BF02389872.
10
A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone.
J Antimicrob Chemother. 1995 May;35(5):569-76. doi: 10.1093/jac/35.5.569.
Zotero 插件